InsidersTradesSigma
Track the Ernexa Therapeutics Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €5.3m. The latest transaction was reported on 17 February 2026 (Acquisition). Among the most active insiders: Cherington Charles. The full history is accessible without an account.
Analysts rate Ernexa Therapeutics Inc. Strong Buy (bullish), based on 1 analysts. Average price target: US$30.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
Ernexa Therapeutics Inc. is a company focused on developing innovative therapeutic treatments. It is listed on the XNAS market.